Tactile Medical (TCMD)
Builds prescribed home-therapy devices for lymphedema and airway clearance.
$22.41
At close+0.16 (+0.72%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70 | 78 | 61 | 73 | 73 | 86 | 61 | 79 | 86 | 104 | 75 | 86 |
| Cost of revenue | 20 | 22 | 18 | 19 | 19 | 21 | 16 | 20 | 21 | 25 | 18 | 27 |
| Gross profit | 49 | 56 | 43 | 54 | 54 | 64 | 45 | 59 | 65 | 79 | 58 | 59 |
| 41 | 44 | 46 | 48 | 47 | 52 | 50 | 55 | 54 | 60 | 59 | 52 | |
| Research & development | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| 42 | 42 | 44 | 45 | 45 | 49 | 48 | 52 | 51 | 59 | 56 | 32 | |
| Selling & marketing | 26 | 27 | 27 | 29 | 27 | 29 | 28 | 30 | 30 | 34 | 33 | 32 |
| General & administrative | 16 | 15 | 16 | 17 | 18 | 20 | 20 | 22 | 21 | 25 | 23 | 0 |
| Other expenses | −3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | −2 | 1 | 18 |
| Operating income | 8 | 12 | −3 | 6 | 7 | 13 | −5 | 4 | 11 | 19 | −2 | 7 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
| Interest income | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Interest expense | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 3 | −1 | −1 | −1 | 0 | −3 | −1 | −1 | 0 | −1 | −1 | −1 |
| Income before tax | 8 | 12 | −3 | 6 | 7 | 13 | −4 | 5 | 11 | 19 | −1 | 7 |
| Income tax expense | −15 | 4 | −1 | 2 | 2 | 3 | −1 | 1 | 3 | 9 | 1 | 0 |
| Net income from continuing operations | 22 | 8 | −2 | 4 | 5 | 10 | −3 | 3 | 8 | 11 | −2 | 8 |
| Net income | 22 | 8 | −2 | 4 | 5 | 10 | −3 | 3 | 8 | 11 | −2 | 8 |
| EPS, basic | $0.95 | $0.35 | −$0.09 | $0.18 | $0.21 | $0.40 | −$0.13 | $0.14 | $0.36 | $0.47 | −$0.08 | $0.34 |
| EPS, diluted | $0.94 | $0.35 | −$0.09 | $0.18 | $0.21 | $0.40 | −$0.13 | $0.14 | $0.36 | $0.46 | −$0.08 | $0.34 |
| Weighted average shares, basic | 23 | 23 | 24 | 24 | 24 | 24 | 24 | 23 | 23 | 22 | 23 | 23 |
| Weighted average shares, diluted | 24 | 23 | 24 | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 23 | 23 |
| EBITDA | 7 | 14 | −1 | 8 | 9 | 18 | −2 | 7 | 13 | 21 | 1 | 9 |
| Depreciation & amortization | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBIT | 5 | 12 | −2 | 7 | 7 | 16 | −4 | 5 | 11 | 19 | −1 | 7 |